FSMN(@faststocknewss):PMV PHARMACEUTICALS $PMVP REPORTS 46% ORR IN OVARIAN CANCER TRIAL Updated interim data from the PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy, per the company. - Objective response rate: 46% among 76 ovarian cancer patients - Median time to response: 1.3 months - Median duration of response: 10.0 months - Discontinuation rate due to adverse events: 5%

FSMN

@faststocknewss

The Fastest Stock Market News Account on X

Joined November 2021

4.7K Following 119.2K Followers

FSMN@faststocknewss

2026.08.31 20:02

PMV PHARMACEUTICALS $PMVP REPORTS 46% ORR IN OVARIAN CANCER TRIAL Updated interim data from the PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy, per the company. - Objective response rate: 46% among 76 ovarian cancer patients - Median time to response: 1.3 months - Median duration of response: 10.0 months - Discontinuation rate due to adverse events: 5%